A CDMO championing a commitment to patients may sound like lip service or branding, but truly patient-centric CDMOs offer ...

Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to ...

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the ...

Background IBD is characterised by recurrent flares, but evidence on whether modifiable dietary factors influence flare risk is limited. Objective The PREdiCCt study was designed to examine ...

Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...

Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings ...

A Michigan-based deliberative study found strong public support for patient-informed artificial intelligence (AI) labeling in health care, emphasizing transparency, privacy, equity, and safety to ...

How much should psychedelics researchers disclose about their personal use of psilocybin, ketamine, and other drugs?

DONGGUAN, GUANGDONG, CHINA, January 15, 2026 /EINPresswire.com/ -- As sleep disorders such as obstructive sleep apnea ...

Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of Opht ...

The Trump administration rightly recognizes that American health care needs reform and greater patient power over expenditures, but the plan it offers is skeletal and needs improvement. It should ...

ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential for ...